Success Metrics

Clinical Success Rate
100.0%

Based on 1 completed trials

Completion Rate
100%(1/1)
Active Trials
4(67%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_2
4
67%
Ph phase_1
2
33%

Phase Distribution

2

Early Stage

4

Mid Stage

0

Late Stage

Phase Distribution6 total trials
Phase 1Safety & dosage
2(33.3%)
Phase 2Efficacy & side effects
4(66.7%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

50.0%

1 of 2 finished

Non-Completion Rate

50.0%

1 ended early

Currently Active

4

trials recruiting

Total Trials

6

all time

Status Distribution
Active(4)
Completed(1)
Terminated(1)

Detailed Status

Recruiting2
Active, not recruiting2
Withdrawn1
Completed1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
4
Success Rate
100.0%
Most Advanced
Phase 2

Trials by Phase

Phase 12 (33.3%)
Phase 24 (66.7%)

Trials by Status

recruiting233%
active_not_recruiting233%
withdrawn117%
completed117%

Recent Activity

4 active trials
Showing 5 of 6
completedphase_1

Enasidenib in Combination With Cobimetinib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia

NCT05441514
recruitingphase_2

Enasidenib (AG-221) Maintenance Post Allogeneic HCT in Patients With IDH2 Mutation

NCT03728335
recruitingphase_2

Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation

NCT03683433
active_not_recruitingphase_2

Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Patients With an IDH2 Mutation

NCT04203316
active_not_recruitingphase_2

CPX-351 Plus Enasidenib for Relapsed AML

NCT03825796
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT05441514Phase 1

Enasidenib in Combination With Cobimetinib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia

Completed
NCT03728335Phase 2

Enasidenib (AG-221) Maintenance Post Allogeneic HCT in Patients With IDH2 Mutation

Recruiting
NCT03683433Phase 2

Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation

Recruiting
NCT04203316Phase 2

Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Patients With an IDH2 Mutation

Active Not Recruiting
NCT03825796Phase 2

CPX-351 Plus Enasidenib for Relapsed AML

Active Not Recruiting
NCT04655391Phase 1

Glasdegib-Based Treatment Combinations for the Treatment of Patients With Relapsed Acute Myeloid Leukemia Who Have Undergone Hematopoietic Cell Transplantation

Withdrawn

All 6 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
6